Rafferty Asset Management, LLC Cel Sci Corp Transaction History

Rafferty Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.93 - $7.7 $950,883 - $1.86 Million	-241,955 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$7.1 - $12.82 $205,956 - $371,882	29,008 Added 13.62%	241,955 $1.72 Million
Q3 2021 Nov 10, 2021	BUY	$7.64 - $12.49 $729,627 - $1.19 Million	95,501 Added 81.31%	212,947 $2.34 Million
Q2 2021 Aug 10, 2021	SELL	$8.68 - $27.49 $237,684 - $752,758	-27,383 Reduced 18.91%	117,446 $1.02 Million
Q1 2021 May 10, 2021	BUY	$12.0 - $27.64 $1.5 Million - $3.45 Million	124,918 Added 627.38%	144,829 $2.2 Million

Q4 2020 Feb 10, 2021	SELL	$11.05 - $16.62 $294,515 - $442,972	-26,653 Reduced 57.24%	19,911 $232,000
Q3 2020 Nov 13, 2020	BUY	$11.69 - $14.54 $146,709 - $182,477	12,550 Added 36.9%	46,564 $594,000
Q2 2020 Aug 07, 2020	BUY	$9.75 - $17.6 $331,636 - $598,646	34,014 New	34,014 $507,000

7.5M

61.8K

141K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $47.3M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.